Induction of Gut Permeability by an Oral Vaccine
NCT04083950
Active Not Recruiting
This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal barrier and response of the immune system. Intestinal and whole-body responses will be measured in all participants before and after the vaccine.
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
05/14/2025
Locations: USDA, ARS, Western Human Nutrition Research Center, Davis, California
Conditions: Intestinal Permeability, Inflammation, Vaccine, Typhoid Fever
Register for Updates
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
NCT05089630
Completed
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation manner, based upon safety adjudication.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/12/2025
Locations: GSK Investigational Site, Anaheim, California +17 locations
Conditions: Cytomegalovirus Infections
Register for Updates
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
NCT05972993
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/08/2025
Locations: GSK Investigational Site, San Diego, California +3 locations
Conditions: COVID-19
Register for Updates
Clinical Trials of Multivalent Opioid Vaccine Components
NCT04458545
Recruiting
Currently, abuse of prescription opioid analgesics and heroin is a serious problem in the U.S. Although several medications, including methadone, buprenorphine, and naltrexone, are available and effective in treating opioid use disorder (OUD), long-term relapse rates remain high. The current study is designed to examine a new approach to treating OUD, namely use of a vaccine targeted against oxycodone \[Oxy(Gly)4-sKLH\], one of the most commonly abused prescription opioids. The vaccination appro... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
05/07/2025
Locations: Clinilabs Drug Development Corporation, Eatontown, New Jersey +1 locations
Conditions: Opioid-use Disorder
Register for Updates
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
NCT06959563
Active Not Recruiting
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.
Gender:
FEMALE
Ages:
Between 24 years and 64 years
Trial Updated:
05/07/2025
Locations: Medicine Invention Design, Inc., Rockville, Maryland
Conditions: HPV Infection
Register for Updates
The Impact of COVID-19 on Maternal and Neonatal Outcomes
NCT05197621
Recruiting
The novel coronavirus (SARS-CoV-2) infection (COVID-19) has caused a worldwide pandemic. There is still much that is unknown regarding the virus, especially its effects on pregnancy, the fetus, and the neonate. This study seeks to evaluate adverse pregnancy and neonatal outcomes related to COVID-19 infection. The FDA has authorized emergency use authorization for the SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccines from Pfizer and Moderna. Pregnant women were excluded from the Phase III cl... Read More
Gender:
FEMALE
Ages:
Between 14 years and 55 years
Trial Updated:
05/06/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: COVID-19, Pregnancy; Infection
Register for Updates
Retail COVID-19 Study
NCT06761612
Active Not Recruiting
Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be assessed. This study aims to fill these gaps by determining correlates of protection (CoP), assessing the infrastructure's capability, and examining demographic and geographic differences in participatio... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
05/06/2025
Locations: Walgreens - 3298 S John Young Pkwy, Kissimmee, Florida +19 locations
Conditions: COVID - 19
Register for Updates
Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults
NCT05879107
Completed
The purpose of this study is to assess the ability of RSVPreF3 OA investigational vaccine to generate an immune response when given in combination with PCV20 and its safety in older adults, aged ≥60 years of age.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
05/06/2025
Locations: GSK Investigational Site, Guntersville, Alabama +37 locations
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT03384914
Active Not Recruiting
The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival). Participants will be assigned to receive one of two study vaccines (DC1 study vaccine vs. WOKVAC). The study vaccine will be administered in two phases: a study vaccination phase and a booster phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida +6 locations
Conditions: Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Register for Updates
A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence
NCT04298606
Recruiting
This early phase I trial studies the side effects of a vaccine called CIMAvax-EGF and to see how well it works in preventing lung cancer from developing in patients at high risk for lung cancer or coming back (recurrence) in stage IB-IIIA non-small cell lung cancer survivors. In many cancers such as lung cancer, there is a protein receptor called EGFR (epidermal growth factor receptor) that is overexpressed within these cancers. Activation of EGFR has shown to lead to tumor growth and developmen... Read More
Gender:
ALL
Ages:
Between 50 years and 79 years
Trial Updated:
04/29/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Chronic Obstructive Pulmonary Disease, Lung Non-Small Cell Carcinoma, Pneumonia, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Register for Updates
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
NCT04580771
Active Not Recruiting
This phase IIA trial studies the effect of a vaccine (PDS0101) when given together with chemotherapy and radiation therapy (chemoradiation) in treating patients with stage IB3-IVA cervical cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. PDS0101 is a type of vaccine... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
Register for Updates
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
NCT03036930
Active Not Recruiting
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
04/26/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +5 locations
Conditions: Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Register for Updates